Neurocrine Biosciences, Inc’s recently made public that its Chief Regulatory Officer Delaet Ingrid unloaded Company’s shares for reported $61695.0 on Jul 10 ’25. In the deal valued at $135.00 per share,457 shares were sold. As a result of this transaction, Delaet Ingrid now holds 4,730 shares worth roughly $0.63 million.
Then, Onyia Jude sold 59,819 shares, generating $7,803,688 in total proceeds. Upon selling the shares at $130.46, the Chief Scientific Officer now owns 18,289 shares.
Before that, INGRID DELAET bought 457 shares. Neurocrine Biosciences, Inc shares valued at $61,014 were divested by the Officer at a price of $133.51 per share.
Truist initiated its Neurocrine Biosciences, Inc [NBIX] rating to a Buy in a research note published on July 21, 2025; the price target was $163. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in early July with a ‘”a Buy”‘ rating. Needham also remained covering NBIX and has increased its forecast on April 15, 2025 with a “Buy” recommendation from previously “Hold” rating. RBC Capital Mkts revised its rating on April 14, 2025. It rated NBIX as “an Outperform” which previously was an “a Sector perform”.
Price Performance Review of NBIX
On Friday, Neurocrine Biosciences, Inc [NASDAQ:NBIX] saw its stock jump 0.38% to $132.14. Over the last five days, the stock has gained 0.09%. Neurocrine Biosciences, Inc shares have fallen nearly -9.14% since the year began. Nevertheless, the stocks have fallen -3.19% over the past one year. While a 52-week high of $157.98 was reached on 01/30/25, a 52-week low of $84.23 was recorded on 04/09/25.
Levels Of Support And Resistance For NBIX Stock
The 24-hour chart illustrates a support level at 130.89, which if violated will result in even more drops to 129.63. On the upside, there is a resistance level at 133.26. A further resistance level may holdings at 134.37.
How much short interest is there in Neurocrine Biosciences, Inc?
A steep rise in short interest was recorded in Neurocrine Biosciences, Inc stocks on 2025-07-15, dropping by -0.26 million shares to a total of 3.23 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 3.5 million shares. There was a decline of -8.07%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on February 11, 2025 when Deutsche Bank began covering the stock and recommended ‘”a Hold”‘ rating along with a $138 price target.
